About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) has been publicly traded since 1991, making it a 35-year-old public company. It operates in the Biotechnology industry within the Healthcare sector. The company is headquartered in Tarrytown, United States and employs approximately 15,410 people. With a market capitalization of $79 billion, REGN is a large established company.
Key Statistics
- Current Price
- $747.40
- Market Cap
- $79.01B
- 52-Week High
- $821.11
- 52-Week Low
- $476.49
- Sector
- Healthcare
- Industry
- Biotechnology
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -3.05% | $770.94 | $747.40 |
| 2025 | +8.96% | $707.55 | $770.94 |
| 2024 | -18.90% | $872.40 | $707.55 |
| 2023 | +21.73% | $716.65 | $872.40 |
| 2022 | +14.25% | $627.28 | $716.65 |
| 2021 | +30.72% | $479.87 | $627.28 |
| 2020 | +28.66% | $372.96 | $479.87 |
| 2019 | +0.53% | $370.99 | $372.96 |
| 2018 | -0.65% | $373.44 | $370.99 |
| 2017 | +2.42% | $364.63 | $373.44 |
| 2016 | -32.38% | $539.23 | $364.63 |
| 2015 | +32.33% | $407.50 | $539.23 |
| 2014 | +49.05% | $273.39 | $407.50 |
| 2013 | +60.89% | $169.92 | $273.39 |
| 2012 | +208.62% | $55.06 | $169.92 |
| 2011 | +68.84% | $32.61 | $55.06 |
| 2010 | +35.77% | $24.02 | $32.61 |
| 2009 | +31.70% | $18.24 | $24.02 |
| 2008 | -23.98% | $23.99 | $18.24 |
| 2007 | +20.33% | $19.94 | $23.99 |
| 2006 | +26.23% | $15.79 | $19.94 |
| 2005 | +72.64% | $9.15 | $15.79 |
| 2004 | -37.39% | $14.61 | $9.15 |
| 2003 | -20.53% | $18.39 | $14.61 |
| 2002 | -34.27% | $27.97 | $18.39 |
| 2001 | -20.15% | $35.03 | $27.97 |
| 2000 | +176.59% | $12.66 | $35.03 |
| 1999 | +72.88% | $7.33 | $12.66 |
| 1998 | -13.87% | $8.51 | $7.33 |
| 1997 | -46.90% | $16.02 | $8.51 |
| 1996 | +26.47% | $12.66 | $16.02 |
| 1995 | +325.00% | $2.98 | $12.66 |
| 1994 | -80.65% | $15.40 | $2.98 |
| 1993 | +29.17% | $11.92 | $15.40 |
| 1992 | -33.79% | $18.00 | $11.92 |
Valuation
REGN currently trades at a trailing P/E ratio of 18.0, which is considered moderate relative to the broader market. The forward P/E of 14.1 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 2.4. The price-to-sales ratio is 5.5.
Dividends
Regeneron Pharmaceuticals, Inc. pays a dividend to shareholders with a current yield of 0.50%. This translates to $3.76 per share annually. The payout ratio of 8% indicates sustainable dividend coverage.
Risk & Volatility
REGN has a beta of 0.40, indicating it is less volatile than the overall market. The stock's 52-week range is $476.49 to $821.11, and it currently trades in the upper half of its 52-week range.
Analyst Ratings
Based on 27 analyst opinions, REGN has a consensus "buy" rating. The average price target of $872.85 suggests 17.0% upside from current levels.
Frequently Asked Questions
What does Regeneron Pharmaceuticals, Inc. do? ▼
Regeneron Pharmaceuticals, Inc. is a Biotechnology company operating in the Healthcare sector. The company is headquartered in Tarrytown, United States.
What sector is REGN in? ▼
REGN operates in the Healthcare sector, specifically in the Biotechnology industry.
When did REGN go public? ▼
Regeneron Pharmaceuticals, Inc. went public in 1991, making it a 35-year-old public company as of 2026.
How much would $1,000 invested in REGN 5 years ago be worth today? ▼
A $1,000 investment in REGN five years ago would be worth approximately $1,599 today, representing a 59.9% return.
Does REGN pay dividends? ▼
Yes, Regeneron Pharmaceuticals, Inc. pays a dividend with a current yield of 0.50%, which is $3.76 per share annually.
What is REGN's market cap? ▼
Regeneron Pharmaceuticals, Inc. has a market capitalization of $79 billion, classifying it as a large-cap company.
What is REGN's P/E ratio? ▼
REGN has a trailing P/E ratio of 18.0 and a forward P/E of 14.1, which measures how much investors are paying per dollar of earnings.
Is REGN a buy, hold, or sell? ▼
Based on 27 opinions, REGN has a consensus "buy" rating. The average price target is $872.85.
Last updated: 3/14/2026